CHARTING NEW PATHS TOWARD PATIENT IMPACT.

Iantrek was founded by ophthalmic innovator Sean Ianchulev, MD MPH, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai.

OUR Mission

We're committed to significantly impacting unmet needs in chronic eye disease by empowering surgeons with breakthrough solutions.

“Micro-interventional nitinol instrumentation offers new opportunities for anterior segment surgery. AlloFlo Uveo with the Allosert Uveo delivery system allow surgeons unprecedented interventional access and control.”

Dr. Farrell C. Tyson
Tyson Eye Center

“AlloFlo Uveo with the Allosert Uveo delivery system offers unprecedented ease of use and access to the uveoscleral space. Cyclodialysis cleft formation and reinforcement is precise, controlled and atraumatic.”

Dr. Ike Ahmed
Chief Medical Officer

“Iantrek has developed a best-in-class micro-interventional system for a dual-outflow MIGS surgery.”

Dr. David Chang
Advisor, Past President of ASCRS

“We are back to the future... in the uveoscleral space! Iantrek’s micro-interventional technology opens new horizons in interventional glaucoma. Cyclodialysis creation, durable cleft maintenance and high-precision bio-tissue trephination in a hardware-free surgical approach can be a game-changer.”

Dr. Robert Weinreb
Chairman and Director
Shiley Eye Institute

Board of directors

Dr. Sean Ianchulev

Chairman of the Board
Professor, New York Eye & Ear Institute
CMO

Adam Szaronos

Board Member
CEO

Casey Tansey

Board Member

General Partner, USVP

Todd Sone

Board Member

General Partner, aMoon

Jeffry Weinhuff

Board Member

Partner, Visionary Ventures

Marc-André Marcotte

Board Member

Sectoral Asset Management

Partner & Chief Operating Officer

Jim Mazzo

Board Member

Executive Chairman, Neurotech Pharmaceuticals

Dr. Robert Weinreb

Board Member

Shiley Eye Institute

Andrew Corley

Observer

Co-Founder, Flying-L Partners

Dr. Stephen Bloch

Observer

General Partner, Canaan Partners

Pipeline

Harnessing the intrinsic power of natural allogeneic biotissue and applying high-precision micro-interventional technology, we have created a new surgical category of Bio-intervention™ which can impact and reimagine conventional surgical paradigms.
UVEOSCLERAL
Product Development
First-In Human
Commercially Available
AlloFlo™ Uveo
AlloSert™ Uveo
TRABECULAR
Product Development
First-In Human
Commercially Available
Project Erie
C-Rex
C-Rex Duo
UVEOSCLERAL
AlloFlo™ Uveo
AlloSert™ Uveo
Product Development
First-In Human
Commercially Available
TRABECULAR
Project Erie
C-Rex
C-Rex Duo
Product Development
First-In Human
Commercially Available